- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Dermatology Therapeutics: Updates for Primary Care from AAD 2025
Research included new findings on topical and systemic treatments for atopic dermatitis, psoriasis, alopecia areata, and other chronic skin disorders.
At the 2025 American Academy of Dermatology (AAD) Annual Meeting, exciting advancements in dermatologic therapies were unveiled for a variety of skin conditions, including atopic dermatitis (AD), psoriasis, hidradenitis suppurativa, and prurigo nodularis. This year’s highlights include promising results from late-stage clinical trials with novel oral, topical, and systemic treatments—such as phosphodiesterase-4 inhibitor roflumilast cream 1% for refractory AD, OX40 inhibitor rocatinlimab for moderate-to-severe AD, and triple cytokine inhibitor bimekizumab for long-term plaque psoriasis control. In the slides above, Patient Care© Online breaks down the key clinical findings for primary care clinicians.
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial
December 8th 2025KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.
